Maximizing the value of diagnostics in Alzheimer's disease drug development

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Profit and loss calculation for a hypothetical AD therapy.

References

  1. 1

    Hurko, O. & Jones, G. K. Valuation of biomarkers. Nature Rev. Drug Discov. 10, 253–254 (2011).

  2. 2

    Boise, L. et al. Dementia assessment in primary care: results from a study in three managed care systems. J. Gerontol. A Biol. Sci. Med. Sci. 59, M621–M626 (2004).

  3. 3

    Hampel, H. et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nature Rev. Drug Discov. 9, 560–574 (2010).

  4. 4

    Beckett, L. A. et al. The Alzheimer's disease neuroimaging initiative: annual change in biomarkers and clinical outcomes. Alzheimers Dement. 6, 257–264 (2010).

  5. 5

    Dimasi, J. A. et al. Trends in risks associated with new drug development: success rates for investigational drugs. Clin. Pharmacol. Ther. 87, 272–277 (2010).

Download references

Author information

Correspondence to Eric M. Snyder.

Ethics declarations

Competing interests

Eric M. Snyder is an employee of Leerink Swann Consulting LLC, which serves a large number of pharmaceutical and biotech clients worldwide.

Frank S. David is an employee of Leerink Swann Consulting LLC, a life sciences consultancy that serves a large number of biopharmaceutical, medical technology, tools and diagnostics companies worldwide.

Jake Olin is an employee of Leerink Swann Consulting LLC, a life sciences consultancy that serves a large number of biopharmaceutical, medical technology, tools and diagnostics companies worldwide.

Supplementary information

Supplementary information S1

Impact of a diagnostic on the profit and loss calculation for an AD therapy (PDF 601 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Snyder, E., Olin, J. & David, F. Maximizing the value of diagnostics in Alzheimer's disease drug development. Nat Rev Drug Discov 11, 183–184 (2012) doi:10.1038/nrd3535

Download citation

Further reading